Cathelicidin – A Novel Potential Marker of Pediatric Inflammatory Bowel Disease
Authors Krawiec P, Pac-Kożuchowska E
Received 26 October 2020
Accepted for publication 18 December 2020
Published 22 January 2021 Volume 2021:14 Pages 163—174
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Ning Quan
Paulina Krawiec, Elżbieta Pac-Kożuchowska
Department of Pediatrics and Gastroenterology, Medical University of Lublin, Lublin, Poland
Correspondence: Paulina Krawiec
Department of Pediatrics and Gastroenterology, Medical University of Lublin, Racławickie 1, Lublin 20-059, Poland
Tel +48 81 71 85 400
Fax +48 81 74 31 353
Introduction: Cathelicidin is a multifunctional host defense peptide which may also exert pro-inflammatory signals and contribute to the development of autoimmune disorders. We aimed to assess serum concentration of cathelicidin in children with inflammatory bowel disease (IBD) compared to healthy controls and to evaluate its relationship with disease activity and phenotype.
Patients and Methods: The study group included 68 children with IBD. The control group comprised 20 children with functional abdominal pain. All patients and controls were tested for complete blood count, C-reactive protein, erythrocyte sedimentation rate and cathelicidin. Stool samples were collected to assess calprotectin.
Results: Cathelicidin was significantly increased in patients with ulcerative colitis (1073.39± 214.52 ng/mL) and Crohn’s disease (1057.63± 176.03 ng/mL) patients compared to controls (890.56± 129.37 ng/mL) (H=16.28; p=0.0003). Cathelicidin was significantly elevated in children with active IBD (1044.90± 176.17 ng/mL) and IBD remission (1098.10± 227.87 ng/mL) compared to controls (Z=3.21; p=0.001; Z=− 4.12; p< 0.0001, respectively). Negative correlation between cathelicidin and calprotectin in children with ulcerative colitis was found (R=− 0.39; p=0.02). Cathelicidin exhibited AUC of 0.815 for differentiation children with ulcerative colitis from the control group.
Conclusion: Serum cathelicidin is increased in children with Crohn’s disease and ulcerative colitis regardless of clinical activity of the disease suggesting that it may be a potential biomarker of IBD. Inverse correlation between cathelicidin and fecal calprotectin may imply a disparate role of these molecules in the pathophysiology of pediatric ulcerative colitis.
Keywords: antibacterial peptides, Crohn’s disease, LL-37, ulcerative colitis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]